Document is current

Article History

Received: 11 December 2024

Accepted: 18 April 2025

First Online: 2 May 2025

Declarations

:

: The trial protocol was approved by local certified review boards, and the trial was conducted in compliance with the Declaration of Helsinki and the Clinical Trial Act of Japan. After the patients were initially screened for eligibility based on their prior medical records, they were adequately informed of the trial plan and provided written consent.

: Not applicable.

: H.T. has received honoraria from Abbott Medical Japan, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Kowa, Medtronic, and Nihon Medi-Physics. A.T. has received honoraria from Boehringer Ingelheim Japan, Mochida, and Amgen; research funding from Bristol Myers Squibb and Novo Nordisk; A.T. is an Editorial Board member of the journal and not involved in handling this manuscript during the submission and review processes. K.T. has received outsourcing fees from Organization for Clinical Medicine Promotion. N.K. has received honoraria from Sumitomo, Novo Nordisk, Taisho, Eli Lilly Japan, Bayer, Boehringer Ingelheim, Kowa, Daiichi Sankyo, Astellas, MSD, Teijin, Eisai, Novartis, and Mitsubishi Tanabe. M.S. has received honoraria from Astellas Pharma Inc. Y.O. has received honoraria from Astellas, MSD, Mitsubishi Tanabe, Bayer, Novo Nordisk, Kowa and Eli Lilly Japan. K.N. has received honoraria from AstraZeneca, Bayer, Boehringer Ingelheim Japan, Daiichi Sankyo, Eli Lilly Japan, Kowa, Mitsubishi Tanabe, MSD, Novartis, Novo Nordisk, Otsuka; Research grant from Astellas, Bayer, Boehringer Ingelheim Japan, Fuji Yakuhin, Mochida, Novartis; Scholarship from Abbott Medical, Boehringer Ingelheim Japan, Daiichi Sankyo Healthcare, Mitsubishi Tanabe, Teijin. All other authors have nothing to declare.